{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:45:16Z","timestamp":1792698316015,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.dsx.2021.102275","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T22:38:13Z","timestamp":1631659093000},"page":"102275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period"],"prefix":"10.1016","volume":"15","author":[{"given":"N.","family":"Menghoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-0303","authenticated-orcid":false,"given":"P.","family":"Oriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1647-9031","authenticated-orcid":false,"given":"M.P.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.dsx.2021.102275_bib1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"61","author":"Davies","year":"2019","journal-title":"Diabetologia"},{"issue":"22","key":"10.1016\/j.dsx.2021.102275_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.dsx.2021.102275_bib3","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.dsx.2021.102275_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.dsx.2021.102275_bib5","doi-asserted-by":"crossref","first-page":"p331","DOI":"10.4158\/EP161506.CR","article-title":"Diabetic ketoacidosis in a patient with type 2 diabetes on canagliflozin and dexamethasone","volume":"3","author":"Alexander","year":"2017","journal-title":"AACE Clinical Case Reports volume"},{"key":"10.1016\/j.dsx.2021.102275_bib6","first-page":"6450563","article-title":"Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient presenting with acute pancreatitis","volume":"2018","author":"Badwal","year":"2018","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.dsx.2021.102275_bib7","first-page":"17","article-title":"Euglycemic diabetic ketoacidosis: the clinical concern of SGLT2 inhibitors","volume":"2","author":"Benmoussa","year":"2016","journal-title":"Journal of Clinical and Translational Endocrinology: Case Reports"},{"issue":"1","key":"10.1016\/j.dsx.2021.102275_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dom.13012","article-title":"Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature","volume":"20","author":"Bonora","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"25","key":"10.1016\/j.dsx.2021.102275_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011056","article-title":"Euglycemic diabetic ketoacidosis caused by dapagliflozin: a case report","volume":"97","author":"Chou","year":"2018","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.dsx.2021.102275_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12245-019-0240-0","article-title":"Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature","volume":"12","author":"Diaz-Ramos","year":"2019","journal-title":"Int J Emerg Med"},{"issue":"1","key":"10.1016\/j.dsx.2021.102275_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12245-020-0261-8","article-title":"Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report","volume":"13","author":"Fukuda","year":"2020","journal-title":"Int J Emerg Med"},{"issue":"4","key":"10.1016\/j.dsx.2021.102275_bib12","article-title":"Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature","volume":"11","author":"Gajjar","year":"2019","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.dsx.2021.102275_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1573399814666180726114044","article-title":"Due to empagliflozin, a paradigm shift: case report and review of literature","volume":"15","author":"Hernandez-Quiles","year":"2019","journal-title":"Curr Diabetes Rev"},{"issue":"9","key":"10.1016\/j.dsx.2021.102275_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jfma.2018.02.004","article-title":"Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: the first report in a type 2 diabetic (T2DM) Taiwanese and literature review of possible pathophysiology and contributing factors","volume":"117","author":"Lin","year":"2018","journal-title":"J\u00a0Formos Med Assoc"},{"issue":"8","key":"10.1016\/j.dsx.2021.102275_bib15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/medicina55080462","article-title":"Nephrology consultation for severe SGLT2 inhibitor-induced ketoacidosis in type 2 diabetes: case report","volume":"55","author":"Nappi","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.dsx.2021.102275_bib16","first-page":"3901741","article-title":"Euglycemic diabetic ketoacidosis secondary to dapagliflozin in a patient with colon malignancy","volume":"2019","author":"Papadokostaki","year":"2019","journal-title":"Case Rep Endocrinol"},{"issue":"2","key":"10.1016\/j.dsx.2021.102275_bib17","article-title":"Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin","volume":"5","author":"Pujara","year":"2017","journal-title":"J\u00a0Investig Med High Impact Case Rep"},{"key":"10.1016\/j.dsx.2021.102275_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215340","article-title":"Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin","volume":"2016","author":"Rashid","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.dsx.2021.102275_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014150","article-title":"Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: a case report","volume":"98","author":"Yeo","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.dsx.2021.102275_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/0310057X1804600212","article-title":"Postoperative euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature","volume":"46","author":"Chacko","year":"2018","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"10.1016\/j.dsx.2021.102275_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/0897190017748049","article-title":"Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus receiving oral therapy","volume":"32","author":"Dull","year":"2019","journal-title":"J\u00a0Pharm Pract"},{"issue":"8","key":"10.1016\/j.dsx.2021.102275_bib22","article-title":"Sodium-glucose cotransporter-2 inhibitors and euglycaemic diabetic ketoacidosis in the perioperative period: case report","volume":"11","author":"Jhaveri","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.dsx.2021.102275_bib23","first-page":"95","article-title":"Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy","volume":"4","author":"Pace","year":"2018","journal-title":"J\u00a0Pancreat Cancer"},{"issue":"9","key":"10.1016\/j.dsx.2021.102275_bib24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2021.102275_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12630-017-1018-6","article-title":"Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery","volume":"65","author":"Lau","year":"2018","journal-title":"Can J Anaesth"},{"issue":"2","key":"10.1016\/j.dsx.2021.102275_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1574887113666180314101436","article-title":"Diabetic ketoacidosis in patients with type 2 diabetes on sodium-glucose cotransporter-2 inhibitors - a case series","volume":"13","author":"Sharma","year":"2018","journal-title":"Rev Recent Clin Trials"},{"issue":"4","key":"10.1016\/j.dsx.2021.102275_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.revmed.2019.12.006","article-title":"Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: a series of Belgian clinical cases","volume":"41","author":"Menghoum","year":"2020","journal-title":"Rev Med Interne"},{"issue":"4","key":"10.1016\/j.dsx.2021.102275_bib28","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a south Australian clinical case series and Australian spontaneous adverse event notifications","volume":"41","author":"Meyer","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.dsx.2021.102275_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.diabet.2019.01.001","article-title":"Kim BY, et\u00a0al; DKA Study Group of Gyeonin Branch of the Korean Diabetes Association. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors","volume":"45","author":"Jeon","year":"2019","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.dsx.2021.102275_bib30","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jc.2019-00139","article-title":"SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission","volume":"104","author":"Hamblin","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10166","key":"10.1016\/j.dsx.2021.102275_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.dsx.2021.102275_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.dsx.2021.102275_bib35","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.dsx.2021.102275_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S2213-8587(15)00204-1","article-title":"SGLT inhibition and euglycaemic diabetic ketoacidosis","volume":"3","author":"Hine","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.dsx.2021.102275_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2337\/dc15-1585","article-title":"The time is right for a new classification system for diabetes: rationale and implications of the \u03b2-cell-centric classification schema","volume":"39","author":"Schwartz","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2021.102275_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.dsx.2021.102275_bib39","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1172\/JCI63967","article-title":"Malonyl-CoA: the regulator of fatty acid synthesis and oxidation","volume":"122","author":"Foster","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.dsx.2021.102275_bib40","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dsx.2021.102275_bib41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cmet.2014.03.005","article-title":"Glucagon regulates hepatic kisspeptin to impair insulin secretion","volume":"19","author":"Song","year":"2014","journal-title":"Cell Metabol"},{"issue":"1","key":"10.1016\/j.dsx.2021.102275_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1152\/ajplegacy.1955.184.1.91","article-title":"Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin","volume":"184","author":"Cohen","year":"1956","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.dsx.2021.102275_bib43","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"Perry","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.dsx.2021.102275_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bja\/85.1.109","article-title":"The stress response to trauma and surgery","volume":"85","author":"Desborough","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.dsx.2021.102275_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mehy.2018.02.025","article-title":"SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe, and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant","volume":"114","author":"Finucane","year":"2018","journal-title":"Med Hypotheses"},{"issue":"5","key":"10.1016\/j.dsx.2021.102275_bib46","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2337\/db19-0888","article-title":"Interindividual heterogeneity of SGLT2 expression and function in human pancreatic islets","volume":"69","author":"Saponaro","year":"2020","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.dsx.2021.102275_bib48","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"AMERICAN association OF clinical endocrinologists and AMERICAN college OF endocrinology position statement ON the association OF SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.dsx.2021.102275_bib49","article-title":"Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review","author":"Bamgboye","year":"2020","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121002952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121002952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:15:47Z","timestamp":1761729347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402121002952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1871402121002952"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2021.102275","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2021.102275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102275"}}